ArticleDiscover oncology2025
Differential expression of capecitabine-related metabolic enzymes in hepatocellular carcinoma and its clinical value: a retrospective cohort study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metronomic Capecitabine Triggers Ferroptosis in Hepatocellular Carcinoma Cells Through Inhibition of TYMS.Cancer medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundCapecitabine (CAP) is widely used in cancer treatment for its oral convenience and tumor targeting. However, its effectiveness in hepatocellular carcinoma (HCC) is suboptimal, possibly due to metabolic enzyme expression differences. This study aims to analyze these enzymes' expression differences and explore their correlation with clinical pathological factors, to inform personalized CAP treatment.
methodsThis retrospective study used Immunohistochemistry (IHC) to analyze tumor and non-tumorous samples from HCC patients for CAP metabolic enzyme expression. PRM protein quantification was performed on 10% of samples to validate IHC results. Clinical and pathological data were collected, and multivariable linear regression was used to identify independent risk factors.
resultsThis study analyzed 60 HCC patients with hepatitis B and cirrhosis, revealing significant differences in CAP metabolic enzymes expression between tumor and non-tumorous tissues, with greater individual differences in tumors. Cytidine deaminase (CDA) levels in tumors decreased as liver function deteriorated (P = 0.023), while thymidine phosphorylase (TP) levels increased (P < 0.001). Tumor tissue had lower levels of carboxylesterase 1-2 (CES1-2), CDA, and dihydropyrimidine dehydrogenase (DPYD) but higher TP levels than non-tumorous and normal liver tissues. In tumor tissue, CDA (CV: 118.70%, SD: 3.897) and CES2 (CV: 94.90%, SD: 2.910) showed the greatest individual variability. Multivariable linear regression identified independent risk factors affecting CAP metabolic enzyme expression.
conclusionThis study has found significant variability in the expression of CAP metabolic enzymes across individuals and tissues. Developing a treatment flowchart based on metabolic enzymes provides a foundation for personalized HCC treatment and enhances the effectiveness of CAP therapy. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.